Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 15,644 matching trials from the live ClinicalTrials.gov search.
Conditions
Onychomycosis
Interventions
MOB015B, Vehicle (Placebo Comparator)
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
12 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
33
States / cities
Birmingham, Alabama • Encinitas, California • Fremont, California + 30 more
Conditions
Breast Cancer, Neutropenia
Interventions
F-627, Placebo
Drug
Lead sponsor
EVIVE Biotechnology
Industry
Eligibility
18 Years to 74 Years · Female only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Hidradenitis Suppurativa
Interventions
Sonelokimab (M1095), Adalimumab, Placebo
Drug · Other
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
15
States / cities
Fountain Valley, California • Los Angeles, California • Miami, Florida + 12 more
Terminated Phase 2 Interventional Results available

Denosumab for Breast Cancer With Bone Mets

NCT01952054
Conditions
Breast Cancer
Interventions
Denosumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS), Still Disease
Interventions
Local laboratory testing, Local Lab Tests
Other
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Up to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 14 more
Conditions
HER2 Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Scleroderma, Systemic, Sclerosis, Systemic, Systemic Scleroderma, Systemic Sclerosis, Interstitial Lung Disease
Interventions
Pomalidomide (CC-4047), Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
20
States / cities
Los Angeles, California • Rancho Mirage, California • Newark, Delaware + 17 more
Conditions
Cancer Breast, Cancer Prostate
Interventions
Dietary Supplement: N-111, Placebo
Dietary Supplement · Other
Lead sponsor
Optimal Health Research
Other
Eligibility
25 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
Interventions
NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane, NGM120 100mg with Gemcitabine and Abraxane, NGM120 100mg Q3W, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more
Conditions
Melanoma, Malignant Metastatic Melanoma
Interventions
MEDI--522, Integrin + Dacarbazine
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
25
States / cities
Scottsdale, Arizona • Long Beach, California • San Francisco, California + 20 more
Conditions
Achondroplasia
Interventions
Recifercept
Biological
Lead sponsor
Pfizer
Industry
Eligibility
15 Months to 12 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Irvine, California • Long Beach, California • Torrance, California + 2 more
Conditions
Hypertension, Breast Cancer
Interventions
Telehealth Blood Pressure Monitoring and Food Insecurity
Behavioral
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Jackson, Mississippi
Conditions
Breast Cancer
Interventions
BTX-9341, Fulvestrant
Drug
Lead sponsor
Biotheryx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Rochester, Minnesota • Omaha, Nebraska • Houston, Texas + 3 more
Conditions
Breast Cancer
Interventions
lapatinib ditosylate, fluorescence in situ hybridization, gene expression analysis, mutation analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, cell sorting, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
9
States / cities
Cleveland, Ohio
Conditions
Breast Cancer
Interventions
Zelenectide pevedotin (BT8009)
Drug
Lead sponsor
BicycleTx Limited
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Baltimore, Maryland • Boston, Massachusetts • St Louis, Missouri + 5 more
Completed No phase listed Observational

Clinical Diagnosis of Acute Porphyria

NCT01568554
Conditions
Hereditary Coproporphyria (HCP), Acute Intermittent Porphyria (AIP), Variegate Porphyria (VP)
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
15 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
Conditions
Mucopolysaccharidosis II
Interventions
lymphocyte gene therapy
Genetic
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Neoplasms
Interventions
PF-04518600, PF-04518600 plus PF-05082566
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
24
States / cities
Los Angeles, California • Newport Beach, California • Santa Monica, California + 9 more
Completed Phase 2 Interventional Results available

Neoadjuvant and Adjuvant Checkpoint Blockade

NCT02519322
Conditions
Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage III Acral Lentiginous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Acral Lentiginous Melanoma AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Relatlimab, Therapeutic Conventional Surgery
Biological · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Conditions
Papulopustular Rosacea
Interventions
Secukinumab
Drug
Lead sponsor
Anne Chang
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Redwood City, California
Conditions
Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease
Interventions
Baricitinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Post-operative Pain
Interventions
Bupivacaine, Botulinum Toxins, Analgesics
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
27
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • North Little Rock, Arkansas + 21 more
Conditions
Herpes Labialis
Interventions
Famciclovir
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 18 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
San Diego, California • Chicago, Illinois • Evansville, Indiana + 8 more